In the context of non-small cell lung cancer (NSCLC), combining CDK inhibition with the resulting impact on CDC20 can be a strategic approach to limit the proliferation of cancer cells, potentially enhancing treatment effectiveness [78,79]. This evidence concerns the gene CDC20 and non-small cell lung carcinoma.